INTELLIGENT ONCOLOGY
choose a different vision
Check out our interview with Dr. Fred Hirsch
At CHOSA, Dr. Fred Hirsch is a Key Opinion Leader in lung cancer supporting our work and a valued CHOSA board member.
Dr. Fred Hirsch is a distinguished medical oncologist with renowned expertise in lung cancer. For many years, he was a Professor of Medicine and Pathology at the University of Colorado, served as CEO of the International Association for the Study of Lung Cancer for five years, and now is an Executive Director for the Thoracic Oncology Center at Mount Sinai.
Below is a snippet of our interview with Dr. Hirsch, where he discusses lung cancer, chemotherapy as a treatment, and the growing importance of precision medicine. To watch the full video, click the link below.
We provide a safe and more effective solution for patients in need of platin-treatment
Drug Response Predictor
Discover the future of cancer treatment with DRP® — the first-ever biomarker for cisplatin.
Our patented DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most—at the tumor site—providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our DRP® and advances our mission toward precision oncology.
“We need to figure out how to select the right treatment to the right patients. So that is where the future goes. We are leaving the concept of one size fits all.”
Dr. Fred Hirsch